

## References

### I-14

1. Lingman-Framme J, Fasth A. Subcutaneous immunoglobulin for primary and secondary immunodeficiencies: an evidence-based review. 2013;73(12):1307-19.
2. Souayah N, Hasan A, Khan H, et al. The safety profile of home infusion of intravenous immunoglobulin in patients with neuroimmunologic disorders. *J Clin Neuromuscul Dis*. 2011;12.
3. Ayer G, Souayah N. Efficacy and safety of home infusion of intravenous immunoglobulin in multifocal motor neuropathy: A longitudinal study. *J Amer Academy Neurol*. 2014;10(82). Sup P7.111.
4. Abolhassani H, Sadaghiani MS, Aghamohammadi A, Ochs HD, Rezaei N. Home-based subcutaneous immunoglobulin versus hospital-based intravenous immunoglobulin in treatment of primary antibody deficiencies: systematic review and meta-analysis. *J Clin Immunol*. 2012;32(6):1180-92
5. American Academy of Allergy Asthma & Immunology (AAAAI). 8 guiding principles for effective use of IVIG for patients with primary immunodeficiency.
6. AxelaCare Health Solutions, LLC in collaboration with Bio Products Laboratory (BPL) are currently recruiting patients for a trial to demonstrate monitoring of 5% Treatment Naive Intravenous Immunoglobulin (IVIg) Primary Immunodeficiency Disease (PIDD) Patients Using the CareExchange<sup>®</sup> System: A Pilot Study Using 5% Gammalex<sup>®</sup> IVIG in the Home Setting.
7. Huang YH, Chen HC, Huang KW, et al. Intravenous immunoglobulin for postpolio syndrome: a systematic review and meta-analysis. *BMC Neurol*. 2015;15:39
8. Olyaeemanesh A, Rahmani M, et al. Safety and effectiveness assessment of intravenous immunoglobulin in the treatment of relapsing-remitting multiple sclerosis: A meta-analysis. *Med J Islamic Repub of Iran*. 2016;1-11.
9. Brandt-Wouters E, Gerlach O, Hupperts R. The effect of postpartum intravenous immunoglobulins on the relapse rate among patients with multiple sclerosis. *Int J Gyn Obs*. 2016;194-196.
10. Williams KA, Swedo SE, Farmer CA, et al. Randomized, Controlled Trial of Intravenous Immunoglobulin for Pediatric Autoimmune Neuropsychiatric Disorders Associated With Streptococcal Infections. *J Am Acad Child Adolesc Psychiatry*. 2016;55(10):860-867.
11. Patwa HS, Chaudhry V, Katzberg H, Rae-Grant AD, So YT. Evidence-based guideline: intravenous immunoglobulin in the treatment of neuromuscular disorders: report of the Therapeutics and Technology Assessment

- Subcommittee of the American Academy of Neurology. 2012;27;78(13):1009-15.
12. Elovaara I, Apostolski S, van Doorn P, et al. EFNS guidelines for the use of intravenous immunoglobulin in treatment of neurological diseases. *Eur J Neuro.* 2008;893-908.
  13. American Academy of Allergy Asthma and Immunology. Guidelines for the site of care for administration of IGIV therapy. December 2011.
  14. MCG™ Care Guidelines, 22nd edition, 2018, Home Infusion Therapy, CMT: CMT-0009(SR).
  15. Katzberg H, Rasutis V, Bril V Home IVIG for CIDP: A Focus on Patient Centered Care *Can J Neurol Sci.* 2013;40:384-388.
  16. Polinski JM, Kowal MK, Gagnon M, et al. Home infusion: safe clinically effective, patient preferred, and cost saving. *Healthcare.* 2016.
  17. Van Schaïd I, Bril V, van Geloven N, et al. Subcutaneous immunoglobulin for maintenance treatment in chronic inflammatory demyelinating polyneuropathy (PATH): a randomized, doubleblind, placebo-controlled, phase 3 trial. *Lancet.* 2018;17:35-46.
  18. LS, Biswas S, et al. British Association of Dermatologists' guidelines for the management of Stevens-Johnson syndrome/toxic epidermal necrolysis in children and young people, 2018. *Br J Dermatol.* 2019;181:37-54.
  19. Sanders DB, Wolfe GI, Benatar M, et al. International consensus guidance for management of myasthenia gravis: Executive summary. 2016;87(4):419-25.
  20. Van den Bergh P, van Doorn P, Hadden R, et al. European Academy of Neurology/Peripheral Nerve Society guideline on diagnosis and treatment of chronic inflammatory demyelinating polyradiculoneuropathy: Report of a joint Task Force-Second revision. *J Peripher Nerv Syst.* 2021;26(3):242-268.
  21. Bril V, Hartung HP, Lawo JP, et al. Electrophysiological testing in chronic inflammatory demyelinating polyneuropathy patients treated with subcutaneous immunoglobulin: The polyneuropathy and treatment with Hizentra (PATH) study. *Clin Neurophysiol.* 2021;132(1):226-231.
  22. Clinical Pharmacology™ 2024. Tampa FL: Gold Standard, Inc. Immune Globulin.
  23. Micromedex DrugDex Compendium®. 2024. Immune Globulin.
  24. Immune Globulin In: AHFS Drug Information Online Electronic Medical Library. Bethesda, MD: American Society of Health-System Pharmacists. Updated date February 8, 2021.
  25. Hizentra®, Immune Globulin Subcutaneous (Human) 20% Liquid [package insert]. CSL Behring LLC. Kankakee, IL. Revised 04/2023.
  26. Gamunex®-C, Immune Globulin Injection (Human), 10% Caprylate/Chromatography Purified [package insert]. Grifols Therapeutics Inc. Research Triangle Park, NC. Revised 1/2020.

27. Octagam 10%, Immune Globulin Intravenous (Human) liquid solution for intravenous administration [package insert]. Octapharma USA Inc. Paramus, NJ. Revised 03/2022.
28. Gammagard Liquid, Immune Globulin Infusion (Human), 10% Solution, for intravenous and subcutaneous administration [package insert]. Baxter International Inc. Westlake Village, CA; Revised 03/2023.
29. Privigen<sup>®</sup>, Immune Globulin Intravenous (Human), 10% Liquid [package insert]. CSL Behring LLC. Kankakee, IL. Revised 03/2022.
30. Gammaplex<sup>®</sup> 5% Immune Globulin Intravenous (Human), 5% Liquid, for intravenous use [package insert]. BPL Inc. Raleigh, NC. Revised 09/2019.
31. HyQvia, Immune Globulin Infusion 10% (Human) with Recombinant Human Hyaluronidase Solution, for subcutaneous administration [package insert]. Baxalta US Inc. Lexington, MA. Revised 04/2023.
32. Cuvitru, Immune Globulin Subcutaneous (Human), 20% Solution. [package insert]. Baxalta US Inc. Lexington, MA. Revised 03/2023.
33. Flebogamma DIF, Human normal immunoglobulin [package insert]. Grifols S.A. Barcelona, Spain Revised 07/2017.
34. Bivigam<sup>®</sup>, immune globulin intravenous (human) 10% liquid [package insert]. ADMA Biologics, INC. Ramsey, NJ. Revised 12/2022.
35. Xembify<sup>®</sup>, immune globulin subcutaneous, human-klhw 20% solution [package insert]. Grifols Therapeutics LLC. Research Triangle Park, NC. Revised 8/2020.
36. Asceniv<sup>™</sup>, immune globulin intravenous, human-slra [package insert]. ADMA Biologics, INC. Ramsey, NJ. Revised 04/2019.
37. Cutaquig<sup>®</sup>, immune globulin subcutaneous (human)-hipp [package insert]. Octapharma USA Inc. Paramus, NJ. Revised 11/2021.
38. Panzyga<sup>®</sup>, immune globulin intravenous, human-ifas [package insert]. Pfizer Labs. New York, NY. Revised 01/2021.
39. Alyglo<sup>™</sup>, immune globulin intravenous, human-stwk [package insert]. GC Biopharma Corp. Teaneck, NJ. Revised 12/2023.